Page last updated: 2024-11-13

rosuvastatin lactone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

rosuvastatin lactone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID29918986
CHEBI ID184522
SCHEMBL ID245092
SCHEMBL ID245091
MeSH IDM0548621

Synonyms (29)

Synonym
SOEGVMSNJOCVHT-VEUZHWNKSA-N
n-(4-(4-fluorophenyl)-5-((e)-2-((2s,4r)-4-hydroxy-6-oxotetrahydro-2h-pyran-2-yl)vinyl)-6-isopropylpyrimidin-2-yl)-n-methylmethanesulfonamide
e-6-{2-[2-(n-methyl-n-methanesulfonylamino)-4-(4-fluorophenyl)-6-isopropyl-pyrimidin-5-yl]vinyl}-(4r,6s)-4-hydroxy-3,4,5,6-tetrahydro-2h-pyran-2-one
n-[4-(4-luorophenyl)-5-[(e)-2-[(2s,4r)-4-hydroxy-6-oxooxan-2-yl]ethenyl]-6-propan-2-ylpyrimidin-2-yl]-n-methylmethanesulonamide
rosuvastatin lactone
503610-43-3
CHEBI:184522
n-[4-(4-fluorophenyl)-6-(1-methylethyl)-5-[(1e)-2-[(2s,4r)-tetrahydro-4-hydroxy-6-oxo-2h-pyran-2-yl]ethenyl]-2-pyrimidinyl]-n-methylmethanesulfonamide
rosuvastatin-5s-lactone
AKOS015896316
rosuvastatin lactone [usp impurity]
rosuvastatin calcium impurity d [ep impurity]
n-(4-(4-fluorophenyl)-6-(1-methylethyl)-5-((1e)-2-((2s,4r)-tetrahydro-4-hydroxy-6-oxo-2h-pyran-2-yl)ethenyl)-2-pyrimidinyl)-n-methylmethanesulfonamide
SCHEMBL245092
SCHEMBL245091
unii-fl37w41f3t
fl37w41f3t ,
methanesulfonamide, n-(4-(4-fluorophenyl)-6-(1-methylethyl)-5-((1e)-2-((2s,4r)-tetrahydro-4-hydroxy-6-oxo-2h-pyran-2-yl)ethenyl)-2-pyrimidinyl)-n-methyl-
AC-30584
F19301
n-[4-(4-fluorophenyl)-5-[(e)-2-[(2s,4r)-4-hydroxy-6-oxotetrahydro-2h-pyran-2-yl]ethenyl]-6-(1-methylethyl)pyrimidin-2-yl]-n-methylmethanesulfonamide (rosuvastatin lactone)
rosuvastatin 5 s-lactone
n-[4-(4-fluorophenyl)-5-[(e)-2-[(2s,4r)-4-hydroxy-6-oxooxan-2-yl]ethenyl]-6-propan-2-ylpyrimidin-2-yl]-n-methylmethanesulfonamide
n-[4-(4-fluorophenyl)-5-[(e)-2-[(2s,4r)-4-hydroxy-6-oxotetrahydro-2h-pyran-2-yl]ethenyl]-6-(1-methylethyl)pyrimidin-2-yl]-n-methylmethanesulfonamide
n-[4-(4-fluorophenyl)-5-[(1e)-2-[(2s,4r)-4-hydroxy-6-oxooxan-2-yl]ethenyl]-6-(propan-2-yl)pyrimidin-2-yl]-n-methylmethanesulfonamide
AS-82903
DTXSID901034473
CS-0145597
HY-138166

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"This study was conducted to determine the pharmacokinetic characteristics of rosuvastatin and its metabolites after single and multiple doses of rosuvastatin in healthy Chinese subjects living in China."( Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study.
Chen, WL; Chu, NN; Li, XN; Xu, HR; Zhu, JR, 2010
)
0.36
" Blood samples were obtained within 30 minutes before dosing on days 7, 8, and 9 for the assessment of pharmacokinetic parameters at steady state."( Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study.
Chen, WL; Chu, NN; Li, XN; Xu, HR; Zhu, JR, 2010
)
0.36

Dosage Studied

ExcerptRelevanceReference
" Blood samples were obtained within 30 minutes before dosing on days 7, 8, and 9 for the assessment of pharmacokinetic parameters at steady state."( Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study.
Chen, WL; Chu, NN; Li, XN; Xu, HR; Zhu, JR, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyrimidinesAny compound having a pyrimidine as part of its structure.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's5 (83.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.07 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (50.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other3 (50.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]